Literature DB >> 14750089

Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study.

Martin J Landray1, David C Wheeler, Gregory Y H Lip, David J Newman, Andrew D Blann, Fiona J McGlynn, Simon Ball, John N Townend, Colin Baigent.   

Abstract

BACKGROUND: Studies in the general population suggest that low-grade inflammation, endothelial dysfunction, and platelet activation are associated with an increased risk of cardiovascular events.
METHODS: Markers of inflammation, endothelial dysfunction, and platelet activation were measured in 334 patients with chronic kidney disease (serum creatinine >1.47 mg/dL [>130 micromol/L] at screening) and compared with 2 age- and sex-matched control groups, 1 comprising 92 patients with coronary artery disease and the other comprising 96 apparently healthy individuals with no history of cardiovascular or kidney disease.
RESULTS: There was evidence of low-grade inflammation in the chronic renal impairment group compared with healthy controls, with higher concentrations of C-reactive protein (3.70 versus 2.18 mg/L, P < 0.01) and fibrinogen (3.48 versus 2.67 g/L, P < 0.001) and lower serum albumin concentration (41.8 versus 44.0 g/dL [418 versus 440 g/L], P < 0.001). More severe renal impairment was associated with a trend towards higher fibrinogen and lower albumin concentrations (both P < 0.001), although there was no association with higher C-reactive protein level. As compared to healthy controls, plasma von Willebrand factor (142 versus 108 IU/dL, P < 0.001) and soluble P-selectin concentrations (57.0 versus 43.3 ng/mL, P < 0.001) were also higher in the chronic renal impairment group. More severe renal impairment was associated with a trend towards higher levels of von Willebrand factor (P < 0.001) and of soluble P selectin (P < 0.05).
CONCLUSION: This cross-sectional analysis demonstrates that chronic kidney disease is associated with low-grade inflammation, endothelial dysfunction, and platelet activation, even among patients with moderate renal impairment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750089     DOI: 10.1053/j.ajkd.2003.10.037

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  86 in total

Review 1.  Proteinaceous cysteine protease inhibitors.

Authors:  G Dubin
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

2.  Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

3.  Myocardial stunning following defibrillation threshold testing.

Authors:  Michael Mollerus; Leslee Naslund
Journal:  J Interv Card Electrophysiol       Date:  2007-09-11       Impact factor: 1.900

Review 4.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

5.  Contribution of symmetric dimethylarginine to GFR decline in pediatric chronic kidney disease.

Authors:  Ellen R Brooks; Shannon Haymond; Alfred Rademaker; Christopher Pierce; Irene Helenowski; Rod Passman; Faye Vicente; Bradley A Warady; Susan L Furth; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

6.  Renal function is associated with risk of atrial fibrillation after cardiac surgery.

Authors:  Johann Auer; Gudrun Lamm; Thomas Weber; Robert Berent; Choi-Keung Ng; Michael Porodko; Bernd Eber
Journal:  Can J Cardiol       Date:  2007-09       Impact factor: 5.223

7.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

8.  Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004.

Authors:  Steven Fishbane; Simcha Pollack; Harold I Feldman; Marshall M Joffe
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 8.237

9.  Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.

Authors:  Martin J Landray; Jonathan R Emberson; Lisa Blackwell; Tanaji Dasgupta; Rosita Zakeri; Matthew D Morgan; Charlie J Ferro; Susan Vickery; Puja Ayrton; Devaki Nair; R Neil Dalton; Edmund J Lamb; Colin Baigent; Jonathan N Townend; David C Wheeler
Journal:  Am J Kidney Dis       Date:  2010-10-30       Impact factor: 8.860

10.  Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis.

Authors:  Neeraj Dhaun; Pajaree Lilitkarntakul; Iain M Macintyre; Eline Muilwijk; Neil R Johnston; David C Kluth; David J Webb; Jane Goddard
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.